FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine;

Advanced Search

Select up to three search categories and corresponding keywords using the fields to the right. Refer to the Help section for more detailed instructions.

Search our Collections & Repository

Advanced Search
Custom Query

All these words:

For very narrow results

This exact word or phrase:

When looking for a specific result

Any of these words:

Best used for discovery & interchangable words

None of these words:

Recommended to be used in conjunction with other fields

Language:

Dates

Publication Date Range:

to

Document Data

Title:

Document Type:

Library

Collection:

Series:

People

Author:

Clear All

Query Builder

Query box

Clear All

For additional assistance using the Custom Query please check out our Help Page

i

Superseded

This Document Has Been Replaced By: Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States : recommendations of the Advisory Committee on Immunization Practices (ACIP)

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine;

April 17, 2009
By Centers for Disease Control and Prevention (U.S.)
Source: MMWR. Morbidity and mortality weekly report. 2009; 58(14):374-5.

[HTM]

Select to view the document on External site.

This document file type cannot be previewed

English

Details You May Also Like

Details:

Alternative Title:

MMWR. Morbidity and mortality weekly report
Corporate Authors:

Centers for Disease Control and Prevention (U.S.)
Description:

On December 4, 2008, the Food and Drug Administration (FDA) approved an expanded age indication for the tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) Boostrix (GlaxoSmithKline Biologicals, Rixensart, Belgium). Boostrix is now licensed for use in persons aged 10--64 years as a single-dose booster immunization; the vaccine initially was licensed for persons aged 10--18 years. This announcement summarizes the indications for use of Boostrix. Complete recommendations of the Advisory Committee on Immunization Practices (ACIP) for Tdap vaccines have been described previously (1--3).
Subjects:

[+]

Adolescent Adult Age Factors Child Clinical Trials As Topic Diphtheria-Tetanus-Pertussis Vaccine Drug Approval Humans Immunization Schedule Influenza Vaccines Middle Aged Young Adult
Source:

MMWR. Morbidity and mortality weekly report. 2009; 58(14):374-5.
Document Type:

Journal Article
Name as Subject:

United States. Food and Drug Administration.
Place as Subject:

United States
Collection(s):

Morbidity and Mortality Weekly Report (MMWR) Guidelines and Recommendations
Main Document Checksum:

[+]

urn:sha256:e3b0c44298fc1c149afbf4c8996fb92427ae41e4649b934ca495991b7852b855
File Type:

No Additional Files

More +

Superseded

FDA approval of expanded age indication for a tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine;

Details:

Supporting Files

You May Also Like